Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
From - Laboratory Industry Report
Zika made the FDA headlines this month, with two more tests receiving emergency use authorization…
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
Finding information about the number of Laboratory Acquired Infections (LAIs) and other laboratory injuries in the United States is difficult…
From - Laboratory Industry Report
As usual, the Big 3 of Abbott, Quest and LabCorp were the driving force of M&A activity in the diagnostics industry in the first half of 2017…
From - Laboratory Industry Report
The FDA made a stir in May by approving a cancer drug (Keytruda (pembrolizumab) PD-1/PD-L1 inhibitor from Merck) administered on the basis of a…
By Mike O'Brien bio
Here is my periodic update prepared for interested HR professionals trying to deal with the complex American employment laws…
From - Laboratory Industry Report
When it comes to measuring Dx product effectiveness, few things speak louder than the attitudes of ordering physicians. With that in mind…
From - Laboratory Industry Report
After a relatively slow March and April, business has picked up noticeably in May, June and July with deal volume increasing across all…
From - Laboratory Industry Report
Laboratory test products have been appearing on the shelves of mass retail stores with growing frequency. But the newly announced partnership between Walmart and Quest Diagnostics raises…